8-K: Organovo to Sell FXR Program, Including FXR314, to Eli Lilly for Up to $60 Million

Organovo Holdings, Inc. will sell its FXR program, including lead asset FXR314, to Eli Lilly and Company for an upfront payment and potential milestone payments totaling up to $60 million.

Summary

• Organovo Holdings, Inc. has entered into an asset purchase agreement with Eli Lilly and Company for the sale of its FXR program and related assets.
• Lilly will pay an upfront cash payment of $10 million, with $9 million at closing and $1 million held in escrow for 15 months for indemnification claims.
• Organovo is eligible for up to $50 million in milestone payments contingent upon the achievement of certain development, regulatory, and commercial milestones.
• The asset sale is expected to close within approximately 30 days, subject to customary closing conditions.
• In connection with the asset sale, the parties will also enter a transition services agreement and certain other ancillary agreements at the closing.
• Organovo received a delisting notice from Nasdaq due to not meeting the minimum stockholders' equity requirement.
• Organovo intends to present a compliance plan to Nasdaq, including a potential reverse stock split.
• There is no assurance that Nasdaq will grant a further extension or that Organovo will regain compliance.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the sale of the FXR program is a positive development, the delisting notice from Nasdaq and the uncertainty surrounding compliance with listing requirements temper the overall outlook.

Positives

• The sale of the FXR program to Lilly provides Organovo with an upfront payment of $10 million and the potential for up to $50 million in milestone payments.
• The transaction allows Organovo to focus on other areas of its business.
• Lilly's expertise and resources could accelerate the development and commercialization of FXR314.
• The deal includes the assumption by Lilly of certain liabilities related to the FXR program.

Negatives

• Organovo received a delisting notice from Nasdaq due to not meeting the minimum stockholders' equity requirement.
• There is no assurance that Nasdaq will grant a further extension or that Organovo will regain compliance.
• The sale of the FXR program means Organovo will no longer directly benefit from its future success, beyond the milestone payments.
• The company's Quarterly Report on Form 10-Q for the period ended December 31, 2024, reported stockholders equity of $364,000, significantly below the required $2,500,000.

Risks

• The asset sale is subject to closing conditions, and there is no guarantee that the transaction will be completed.
• The milestone payments are contingent upon the achievement of certain development, regulatory, and commercial milestones, which may not be achieved.
• Organovo may not be able to regain compliance with Nasdaq listing requirements, which could result in delisting.
• The company's compliance plan, including a potential reverse stock split, may not be successful.
• The company faces risks and uncertainties related to forward-looking statements, as detailed in its SEC filings.

Future Outlook

Organovo's future depends on its ability to regain compliance with Nasdaq listing requirements and successfully execute its business strategy following the sale of the FXR program. The company will focus on other areas of its business. The success of FXR314 is now dependent on Eli Lilly.

Management Comments

• 'This is a significant milestone for our efforts to advance medicines for IBD using insights from our proprietary 3d human tissue models,' said Keith Murphy, Executive Chairman.
• 'We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development.
• Their world-class development excellence and dedication to delivering for patients will provide an excellent pathway for FXR314 success, and we are pleased to have this opportunity to deliver for patients.'

Industry Context

The sale of Organovo's FXR program to Eli Lilly reflects the ongoing trend of larger pharmaceutical companies acquiring promising assets from smaller biotechnology firms to bolster their pipelines. This deal highlights the value of Organovo's 3D human tissue models in identifying and developing potential drug candidates for inflammatory bowel disease.

Comparison to Industry Standards

• Similar asset purchase agreements in the pharmaceutical industry often include upfront payments, milestone payments, and royalties.
• The specific terms of this deal, such as the size of the upfront payment and the potential milestone payments, are comparable to other transactions involving early-stage drug development programs.
• For example, acquisitions of Phase 2 ready drug programs often command upfront payments in the tens of millions of dollars, with potential milestone payments reaching hundreds of millions, depending on the market potential and stage of development.
• The 15-month escrow period for indemnification claims is a standard practice in M&A transactions to protect the buyer from potential liabilities.

Stakeholder Impact

• Shareholders: The asset sale provides potential upside through milestone payments, but the delisting notice creates uncertainty.
• Employees: The impact on employees is not explicitly mentioned, but the sale of the FXR program may lead to restructuring.
• Customers: The sale of the FXR program may impact the availability of potential treatments for inflammatory bowel disease.
• Suppliers: The sale of the FXR program may impact relationships with suppliers involved in the development and manufacturing of FXR314.
• Creditors: The company's ability to meet its financial obligations may be affected by its compliance with Nasdaq listing requirements.

Next Steps

• Organovo needs to close the asset sale with Eli Lilly.
• Organovo must present a compliance plan to Nasdaq to address the delisting notice.
• Organovo may need to conduct a reverse stock split to regain compliance with the minimum bid price rule.
• Eli Lilly will proceed with Phase 2 development of FXR314.

Key Dates